Karyopharm Therapeutics (KPTI) Cash & Equivalents (2012 - 2026)

Karyopharm Therapeutics (KPTI) has 14 years of Cash & Equivalents data on file, last reported at $47.7 million in Q4 2025.

• Quarterly Cash & Equivalents fell 51.44% year-over-year to $47.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $47.7 million (down 51.44% YoY) and the FY2025 annual result came in at $47.7 million, down 51.44% from the prior year.
• Cash & Equivalents advanced to $47.7 million in Q4 2025, from $35.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $153.3 million in Q1 2022 to a low of $545000.0 in Q3 2023.
• A 5-year average of $55.0 million and a median of $50.0 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2021 — Cash & Equivalents slumped 99.6% — and 2022, when it jumped 18704.42%.
• Tracing KPTI's Cash & Equivalents over 5 years: stood at $6.3 million in 2021, then surged by 2029.28% to $135.2 million in 2022, then slumped by 61.36% to $52.2 million in 2023, then surged by 88.2% to $98.3 million in 2024, then slumped by 51.44% to $47.7 million in 2025.
• The last three Cash & Equivalents figures came in at $47.7 million (Q4 2025), $35.3 million (Q3 2025), and $34.9 million (Q2 2025), per Business Quant data.